PharmiWeb.com - Global Pharma News & Resources
29-Jan-2019

Spero Health Names New Indiana Medical Director and Opens First Clinic in Indianapolis

Spero Health, Inc., an integrated healthcare services organization specializing in local and affordable outpatient care for individuals suffering from substance use disorder, is pleased to announce the appointment of Dr. Darrin Mangiacarne as its new Central Indiana Medical Director.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190129005639/en/

Dr. Darrin Mangiacarne is the new Central Indiana Medical Director for Spero Health, an integrated healthcare services organization specializing in local and affordable outpatient care for individuals suffering from substance use disorder. (Photo: Business Wire)

Dr. Mangiacarne joins Spero Health with an extensive and distinguished background focused on substance use disorders, treatment and prevention. Double board-certified in family medicine and addiction medicine, Dr. Mangiacarne was the Co-chair of the Indiana Attorney General’s Task Force and is the current President of the Indiana Society of Addiction Medicine.

“Our team is fortunate to have Dr. Mangiacarne in this lead role in Indiana,” said Steve Priest, CEO of Spero Health. “His proven leadership and understanding of this patient community, and the providers who care for them, will be instrumental as we continue to meet the unmet need of those suffering from addiction in areas hard hit by the opioid epidemic.”

Indiana is one of four states where the fatal drug overdose rate has more than quadrupled since 1999, according to Indiana University researchers. The total cost of drug overdoses in Indiana exceeds $1 billion a year in medical expenses and lost earnings, according to a study last year by Indiana University’s Richard M. Fairbanks School of Public Health.

Dr. Mangiacarne will help oversee the launch and growth of Spero’s central Indiana locations. He will be providing direct patient care in the Indianapolis clinic located at 8202 Clearvista Parkway Building #6 Suite D, slated to open March 1st. Currently, Spero operates in 3 states providing care for over 5,300 patients each month and is one of the largest office-based opioid treatment providers in the country. The new Indianapolis location will be the 3rd Spero Health outpatient facility in the state of Indiana.

“I am looking forward to joining this dynamic mission-oriented healthcare organization,” said Mangiacarne. “I believe that Spero Health’s individualized, comprehensive approach to treating substance use disorder brings a promising new option to the people who need it in central Indiana.”

For more information on Spero Health, please visit www.sperohealth.com.

About Spero Health - Spero Health, Inc., is an integrated healthcare services organization specializing in local and affordable outpatient care for individuals suffering from substance use disorder with a mission to “Save Lives, Instill Hope, and Restore Relationships.” Spero Health utilizes an innovative evidenced-based integrated care model that combines both physical and behavioral healthcare services under one roof to treat the whole patient. This integrated care model combines physician services (including medication-assisted treatment), behavioral health counseling, recovery support services, medication management and patient and family education. Its community-based approach to treatment allows patients to continue working and caring for their families as they overcome addiction.

Based in Nashville, Tenn. and privately held by Heritage Group, Health Velocity Capital, South Central, Inc. and Frist Cressey Ventures, Spero Health operates 22 freestanding outpatient clinics located throughout Kentucky, Ohio and Indiana. Providing care for more than 5,300 patients each month, Spero is one of the largest office-based opioid treatment providers in the country and is in-network with Medicaid and most commercial insurance plans.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190129005639/en/

Editor Details

Last Updated: 29-Jan-2019